Stockscreener 앱 받기
0.6529
9.82%
0.0584
전일 마감가:
$0.5945
열려 있는:
$0.61
하루 거래량:
3.89M
Relative Volume:
1.85
시가총액:
$59.99M
수익:
-
순이익/손실:
$-40.23M
주가수익비율:
-1.5273
EPS:
-0.4275
순현금흐름:
$-34.82M
1주 성능:
-0.12%
1개월 성능:
-54.97%
6개월 성능:
-59.45%
1년 성능:
-2.57%
1일 변동 폭
$0.5927
$0.671
1주일 범위
$0.5601
$0.7021
52주 변동 폭
$0.5451
$3.62
Context Therapeutics Inc Stock (CNTX) Company Profile
명칭
Context Therapeutics Inc
전화
267-225-7416
주소
2001 MARKET STREET, PHILADELPHIA
Compare CNTX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTX
Context Therapeutics Inc
|
0.6529 | 59.99M | 0 | -40.23M | -34.82M | -0.4275 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Context Therapeutics Inc Stock (CNTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-18 | 개시 | Guggenheim | Buy |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2025-01-08 | 개시 | JMP Securities | Mkt Outperform |
| 2024-11-25 | 개시 | D. Boral Capital | Buy |
| 2024-05-16 | 개시 | Piper Sandler | Overweight |
Context Therapeutics Inc 주식(CNTX)의 최신 뉴스
Context Therapeutics (CNTX) Proxy filing Summary - Quartr
Context Therapeutics (CNTX) Leerink Global Healthcare Conference 2026 Summary - Quartr
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Context Therapeutics hire receives 146,000-share stock option at $0.70 - Stock Titan
Context Therapeutics Advances First-in-Human CT-202 Trial, Setting Up a New Nectin-4 Oncology Catalyst - TipRanks
Context Therapeutics Inc (CNTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes - marketscreener.com
Context Therapeutics Joins Russell 2000, Russell 3000 Indexes - Moomoo
Context Therapeutics stock rises on Russell index inclusion By Investing.com - Investing.com Nigeria
Context Therapeutics stock rises on Russell index inclusion - Investing.com
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes - GlobeNewswire
Context Therapeutics joins Russell 2000 and 3000 indexes - Stock Titan
Diluted net income available to common stockholders of Context Therapeutics, Inc. – DUS:6K9 - TradingView
Maxim Says Context Therapeutics (CNTX)’s Share Pullback Is an Overreaction; Remains Bullish - Yahoo Finance
CNTX Stock Price, Quote & Chart - ChartMill
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2500 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM:CNTX) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 2000 Growth Benchmark - marketscreener.com
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Enterprise value to revenue forward of Context Therapeutics, Inc. – MUN:6K9 - TradingView
Context Therapeutics Inc.(NasdaqCM: CNTX) added to Russell 3000E Index - marketscreener.com
Context Therapeutics Shareholders Approve Stock Increase and Directors - The Globe and Mail
Price to book forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) director receives grant of 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director awarded 45,000 stock options at $0.576 - Stock Titan
Context Therapeutics (CNTX) director Linda West awarded 45K stock options - Stock Titan
Director at Context Therapeutics (CNTX) receives 45,000 stock options award - Stock Titan
Director Philip Kantoff receives 45,000 CNTX stock options at $0.576 exercise price - Stock Titan
Context Therapeutics (NASDAQ: CNTX) wins approval to lift share authorization to 300M - Stock Titan
Context Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Smith Karen L. - Moomoo
Context Therapeutics, Inc. Actuals & Estimates (NASDAQ:CNTX) - TradingView
Price to sales forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Price to sales forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
CNTX Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Context Therapeutics, Inc. – GETTEX:6K9 - TradingView
Price to earnings forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Enterprise value to EBIT forward of Context Therapeutics Inc. – NASDAQ:CNTX - TradingView
Context Therapeutics (CNTX) Rallies 5% as Biotech Stock Tests Key ResistanceMFI Overbought - dars.gov.et
Context Therapeutics Inc (CNTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Context Therapeutics Inc (CNTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Context Therapeutics Inc (CNTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Context Therapeutics Inc (CNTX) Institutional Confidence - TradingKey
Context Therapeutics Inc (CNTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Context Therapeutics Inc (CNTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Context Therapeutics Inc (CNTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Context Therapeutics Inc (CNTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maxim Group Maintains Context Therapeutics(CNTX.US) With Buy Rating, Maintains Target Price $4 - Moomoo
CNTX Maintained by Maxim Group -- Price Target Lowered to $4.00 - GuruFocus
Context Therapeutics Inc (CNTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):